menu toggle

Where Does Direct-to-Patient Fit in a Post-COVID World?

Applied Clinical Trials, Andrea Zobel

As we look forward, questions exist about how the use of direct-to-patient model will evolve—and what is needed to ensure the success of these trials in a rapidly evolving healthcare and clinical trial landscape. In the following Q&A, Andrea Zobel, PhD, Senior Director of Personalized Supply Chain at AmerisourceBergen’s World Courier, a global specialty logistics provider, and Graham Wylie, MBBS, Executive Chairman & Founder of the Medical Research Network (MRN), discuss the demand for decentralized clinical trials (DCTs), the unique challenges and considerations for implementing the model around the world, and how the emergence of technology and data solutions will affect DCT moving forward.

For the full Q&A, please visit Applied Clinical Trials